A5314: Effect of LDMTX on Inflammation in HIV-infected Individuals
Study Location:
Baltimore
Topic:
HIVCardiovascular Disease and HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT01949116?term=a5314&rank=2
IRB#:
NA_00088694
Coordinator:
Ilene Wiggins, RN
Enrollment:
Closed
Trial Period:
Completed
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of LDMTX on endothelial function and inflammation in virologically suppressed HIV-infected participants.
HIV-infected men and women ≥40 years old, who have been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks; who have a CD4+ T-cell count ≥400 cells/mm3; and who have documented CVD or who are at increased CVD risk.
410-955-2898